Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, today reported the preliminary results of its Discovery 2021 program. According to the update, Predictive Oncology’s Helomics subsidiary’s evaluation demonstrated its proprietary artificial intelligence (“AI”) program CoRE(TM) (Computational Research Engine), combined with its tumor profile data and matched ovarian cancer samples, could identify potential new chemotherapy drug uses. Not currently approved for ovarian cancer, the drugs have potential for use in ovarian cancer treatment with further study followed by clinical trial and regulatory approval. The Discovery 2021 program combines Helomics’ proprietary knowledgebase, its AI machine learning program and its TruTumor(TM) platform to create PeDAL(TM) (Patient-centric Discovery by Active Learning), a unique approach to drug discovery. “PeDAL leads to a better selection of drugs, matching the different cancer types to the patients associated with those cancers and potential treatments, improving the scientific and clinical success of drug development,” said J. Melville (Mel) Engle, CEO and chairman of Predictive Oncology. “This also translates to millions of dollars in reduced development costs for our future partners. PeDAL can now deliver a proven system that efficiently drives drug response experiments and pulls patient-centric data into the discovery process.”
To view the full press release, visit https://ibn.fm/0uVUH
About Predictive Oncology Inc.
Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcomes. Using artificial intelligence, Predictive Oncology uses a database of 150,000+ cancer tumors, categorized by patient type, against drug compounds to determine optimal therapies to be used to ultimately eliminate cancer. As the drug discovery community has now realized, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics. Predictive Oncology instead takes a multiomic approach, which considers the vast multitude of factors that make each cancer unique. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
